Diabetic Autonomic Neuropathy (original) (raw)

Semin Neurol 2003; 23(4): 365-372
DOI: 10.1055/s-2004-817720

1Strelitz Diabetes Research Institutes, Eastern Virginia Medical School, Norfolk, Virginia
2Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts

Publication History

Publication Date:
15 April 2004 (online)

ABSTRACT

Diabetic autonomic neuropathy is the most common and troublesome complication of diabetes mellitus. Although involvement of the autonomic nervous system is generally diffuse, symptoms may be confined to a single target organ or organ system. Complications of diabetic autonomic neuropathy contribute greatly to the morbidity, mortality, and reduced quality of life of the person with diabetes and are the major source of increased costs of caring for the diabetic patient. Factors in the pathogenesis of these complications are altered metabolism, vascular insufficiency, loss of growth factor trophism, and autoimmune destruction of nerves in a visceral and cutaneous distribution. The clinical manifestations and the complications of diabetic autonomic neuropathy are reviewed. Future therapeutic strategies that are developed from a better understanding of the pathogenetic processes underlying this disorder can be directed at the cause rather than the manifestations. There are studies in progress that suggest that autonomic nerves can be induced to regenerate, and the future for patients with diabetic autonomic neuropathy is brighter.

KEYWORDS

Diabetes mellitus - autonomic neuropathy - cardiovascular autonomic neuropathy - gastrointestinal autonomic neuropathy - erectile dysfunction - neurogenic bladder

REFERENCES

1 Vinik A I, Maser R E, Mitchell B D, Freeman R. Diabetic autonomic neuropathy. Diabetes Care . 2003; 26 1553-1579
2 Freeman R. Diabetic autonomic neuropathy: an overview. In: Veves A, ed. Clinical Management of Diabetic Neuropathy Totowa, NJ: Humana Press 1998: 181-208
3 Vinik A I, Erbas T. Recognizing and treating diabetic autonomic neuropathy. Cleve Clin J Med . 2001; 68 928-944
4 Vinik A I, Erbas T, Pfeifer M A, Feldman E L, Stevens M J, Russell J W. Diabetic autonomic neuropathy. In: Porte D, Sherwin RS, Baron A, eds. Ellenberg & Rifkin's Diabetes Mellitus 6th ed. New York: McGraw Hill; 2003: 789-804
5 Ewing D J, Clarke B F. Diabetic autonomic neuropathy: present insights and future prospects. Diabetes Care . 1986; 9 648-665
6 Ziegler D. Cardiovascular autonomic neuropathy: clinical manifestations and measurement. Diabetes Reviews . 1999; 7 300-315
7 Pfeifer M A, Weinberg C R, Cook D L. et al . Autonomic neural dysfunction in recently diagnosed diabetic subjects. Diabetes Care . 1984; 7 447-453
8 Dyck P J, Kratz K M, Karnes J L. et al . The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study. Neurology . 1993; 43 817-824
9 Neil H A, Thompson A V, John S, McCarthy S T, Mann J I. Diabetic autonomic neuropathy: the prevalence of impaired heart rate variability in a geographically defined population. Diabet Med . 1989; 6 20-24
10 Ziegler D, Gries F A, Spuler M, Lessmann F. Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study Group: the epidemiology of diabetic neuropathy. J Diabetes Complications . 1992; 6 49-57
11 Greene D A, Lattimer S A, Sima A A. Are disturbances of sorbitol, phosphoinositide, and Na+-K+-ATPase regulation involved in pathogenesis of diabetic neuropathy?. Diabetes . 1988; 37 688-693
12 Cameron N E, Cotter M A. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes . 1997; 46(S2) S31-S37
13 Low P A, Nickander K K, Tritschler H J. The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes . 1997; 46 (suppl 2) S38-S42
14 Hoeldtke R D, Bryner K D, McNeill D R. et al . Nitrosative stress, uric acid, and peripheral nerve function in early type 1 diabetes. Diabetes . 2002; 51 2817-2825
15 Vinik A I, Erbas T, Tae S, Stansberry K, Scanelli J A, Pittenger G L. Dermal neurovascular dysfunction in type 2 diabetes. Diabetes Care . 2001; 24 1468-1475
16 Pittenger G L, Malik R A, Burcus N, Boulton A J, Vinik A I. Specific fiber deficits in sensorimotor diabetic polyneuropathy correspond to cytotoxicity against neuroblastoma cells of sera from patients with diabetes. Diabetes Care . 1999; 22 1839-1844
17 Apfel S C, Arezzo J C, Brownlee M, Federoff H, Kessler J A. Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res . 1994; 634 7-12
18 Horrobin D F. Essential fatty acids in the management of impaired nerve function in diabetes. Diabetes . 1997; 46 (suppl 2) S90-S93
19 Vincenti A M, Brownlee M, Russell J W. Oxidative stress and programmed cell death in diabetic neuropathy. Ann N Y Acad Sci . 2002; 959 368-383
20 Pacher P, Liaudet L, Soriano F G, Mabley J G, Szabo E, Szabo C. The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes . 2002; 51 514-521
21 Du X, Matsumura T, Edelstein D. et al . Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest . 2003; 112 1049-1057
22 Ziegler D, Gries F A, Muhlen H, Rathmann W, Spuler M, Lessmann F. Prevalence and clinical correlates of cardiovascular autonomic and peripheral diabetic neuropathy in patients attending diabetes center. The DiaCAN Multicenter Study Group. Diabetes Metab . 1993; 19 143-151
23 Maser R E, Mitchell B D, Vinik A I, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care . 2003; 26 1895-1901
24 Kahn J, Zola B, Juni J, Vinik A I. Decreased exercise heart rate in diabetic subjects with cardiac autonomic neuropathy. Diabetes Care . 1986; 9 389-394
25 Ewing D J, Boland O, Neilson J M, Cho C G, Clarke B F. Autonomic neuropathy, QT interval lengthening, and unexpected deaths in male diabetic patients. Diabetologia . 1991; 34 182-185
26 Valensi P, Sachs R N, Harfouche B. et al . Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia. Diabetes Care . 2001; 24 339-343
27 Milan Study on Atherosclerosis and Diabetes. (MiSAD) Group: prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic risk factors in noninsulin-dependent diabetes mellitus. Am J Cardiol . 1997; 79 134-139
28 Miettinen H, Lehto S, Salomaa V. et al . Impact of diabetes on mortality after the first myocardial infarction: The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care . 1998; 21 69-75
29 Ewing D J, Martyn C N, Young R J, Clarke B F. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care . 1985; 8 491-498
30 Freeman R, Saul P, Roberts M, Berger R D, Broadbridge C, Cohen R. Spectral analysis of heart rate in diabetic autonomic neuropathy. Arch Neurol . 1991; 48 185-190
31 Risk M, Bril V, Broadbridge C, Cohen A. Heart rate variability measurement in diabetic neuropathy: review of methods. Diabetes Technol Ther . 2001; 3 63-76
32 Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation . 1996; 93 1043-1065
33 Kilo S, Berghoff M, Hilz M, Freeman R. Neural and endothelial control of the microcirculation in diabetic peripheral neuropathy. Neurology . 2000; 54 1246-1252
34 Stansberry K B, Hill M A, Shapiro S A, McNitt P M, Bhatt B A, Vinik A I. Impairment of peripheral blood flow responses in diabetes resembles an enhanced aging effect. Diabetes Care . 1997; 20 1711-1716
35 Stansberry K B, Peppard H R, Babyak L M, Popp G, McNitt P M, Vinik A I. Primary nociceptive afferents mediate the blood flow dysfunction in non-glabrous (hairy) skin of type 2 diabetes: a new model for the pathogenesis of microvascular dysfunction. Diabetes Care . 1999; 22 1549-1554
36 Vinik A I, Erbas T, Park T S, Pierce K K, Stansberry K B. Methods for evaluation of peripheral neurovascular dysfunction. Diabetes Technol Ther . 2001; 3 29-50
37 Maleki D, Locke III R G, Camilleri M. et al . Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch Intern Med . 2000; 160 2808-2816
38 Kong M F, Horowitz M, Jones K L, Wishart J M, Harding P E. Natural history of diabetic gastroparesis. Diabetes Care . 1999; 22 503-507
39 Vinik A, Erbas T, Stansberry K. Gastrointestinal, genitourinary, and neurovascular disturbances in diabetes. Diabetes Reviews . 1999; 7 358-378
40 Lysy J, Israeli E, Goldin E. The prevalence of chronic diarrhea among diabetic patients. Am J Gastroenterol . 1999; 94 2165-2170
41 Bacon C G, Hu F B, Giovannucci E, Glasser D B, Mittleman M A, Rimm E B. Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care . 2002; 25 1458-1463
42 Richardson D, Vinik A. Etiology and treatment of erectile failure in diabetes mellitus. Curr Diab Rep . 2002; 2 501-509
43 Bradley W E. Diagnosis of urinary bladder dysfunction in diabetes mellitus. Ann Intern Med . 1980; 92 323-326
44 Shaw J E, Parker R, Hollis S, Gokal R, Boulton A J. Gustatory sweating in diabetes mellitus. Diabet Med . 1996; 13 1033-1037
45 Cryer P E. Hypoglycemia-associated autonomic failure in diabetes. Am J Physiol Endocrinol Metab . 2001; 281 E1115-E1121
46 DCCT Research Group. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia . 1998; 41 416-423
47 Gaede P, Vedel P, Parving H H, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet . 1999; 353 617-622
48 Ziegler D, Reljanovic M, Mehnert H, Gries F A. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes . 1999; 107 421-430
49 Ebbehoj E, Poulsen P L, Hansen K W, Knudsen S T, Molgaard H, Mogensen C E. Effects on heart rate variability of metoprolol supplementary to on going ACE-inhibitor treatment in type I diabetic patients with abnormal albuminuria. Diabetologia . 2002; 45 965-975
50 Kontopoulos A G, Athyros V G, Didangelos T P. et al . Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy. Diabetes Care . 1997; 20 355-361
51 Malik R A, Williamson S, Abbott C. et al . Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet . 1998; 352 1978-1981
52 Erbas T, Varoglu E, Erbas B, Tastekin G, Akalin S. Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. Diabetes Care . 1993; 16 1511-1514
53 Janssens J, Peeters T L, Vantrappen G. et al . Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med . 1990; 322 1028-1031
54 Shaw J E, Abbott C A, Tindle K, Hollis S, Boulton A J. A randomized controlled trial of topical glycopyrrolate, the first specific treatment for diabetic gustatory sweating. Diabetologia . 1997; 40 299-301
55 Restivo D A, Lanza S, Patti F. et al . Improvement of diabetic autonomic gustatory sweating by botulinum toxin type A. Neurology . 2002; 59 1971-1973